Podcast Episodes
Back to Search
Episode 385: ASCO GU 2025 - TALAPRO-2
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
1 year, 8 months ago
Episode 384: ASCO GU Preview
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
1 year, 8 months ago
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
1 year, 8 months ago
Episode 382: Uromigos Japan - TROPICs-04の考察
残念ながらNegative StudyとなったTROPICs-04についてUromigos Japanの3人が忖度なしに、その原因や理由について考察をします！！
1 year, 8 months ago
Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpo…
1 year, 9 months ago
Episode 380: The Role of SBRT in RCC
Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.
1 year, 9 months ago
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！
1 year, 9 months ago
Episode 378: 2025 Preview of Important GU Data
Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prosta…
1 year, 9 months ago
Episode 377: Prostate Cancer 2024 Highlights
Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss…
1 year, 10 months ago
Episode 376: Bladder Cancer 2024 Highlights
Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.
1 year, 10 months ago